130 related articles for article (PubMed ID: 37259527)
1. Identification of Populations at Risk for "Choosing Un-Wisely": A SEER Population-Based Study.
Hong MJ; Lum SS; Ji L; Namm JP; Solomon NL; Garberoglio C; Vora H
Am Surg; 2023 Oct; 89(10):4135-4141. PubMed ID: 37259527
[TBL] [Abstract][Full Text] [Related]
2. Use of sentinel lymph node biopsy in elderly patients with breast cancer - 10-year experience from a Swiss university hospital.
Heidinger M; Maggi N; Dutilh G; Mueller M; Eller RS; Loesch JM; Schwab FD; Kurzeder C; Weber WP
World J Surg Oncol; 2023 Jun; 21(1):176. PubMed ID: 37287038
[TBL] [Abstract][Full Text] [Related]
3. Omitting axillary staging in selected patients: Rationale of Choosing Wisely in breast cancer treatment.
Grossi S; Le J; Armani A
Surgery; 2023 Aug; 174(2):413-415. PubMed ID: 37169614
[TBL] [Abstract][Full Text] [Related]
4. Using MammaPrint on core needle biopsy to guide the need for axillary staging during breast surgery.
Drapalik LM; Miller ME; Rock L; Li P; Simpson A; Shenk R; Amin AL
Surgery; 2024 Mar; 175(3):579-586. PubMed ID: 37852835
[TBL] [Abstract][Full Text] [Related]
5. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy.
Rescigno J; Zampell JC; Axelrod D
Ann Surg Oncol; 2009 Mar; 16(3):687-96. PubMed ID: 19101768
[TBL] [Abstract][Full Text] [Related]
6. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
[TBL] [Abstract][Full Text] [Related]
10. Axillary regional recurrence after sentinel lymph node biopsy for breast cancer.
Rosing DK; Dauphine CE; Vargas MP; Gonzalez K; Burla M; Kaufmann P; Vargas HI
Am Surg; 2006 Oct; 72(10):939-42. PubMed ID: 17058740
[TBL] [Abstract][Full Text] [Related]
11. De-escalation of axillary surgery in patients outside Z0011 criteria.
Giannakou A; Gooch J; Gergelis KR; Weiss A
Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
[TBL] [Abstract][Full Text] [Related]
12. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.
Yi M; Giordano SH; Meric-Bernstam F; Mittendorf EA; Kuerer HM; Hwang RF; Bedrosian I; Rourke L; Hunt KK
Ann Surg Oncol; 2010 Oct; 17 Suppl 3(0 3):343-51. PubMed ID: 20853057
[TBL] [Abstract][Full Text] [Related]
13. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
Mann JM; Wu X; Christos P; Nagar H
Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
[TBL] [Abstract][Full Text] [Related]
14. Sentinel lymph node biopsy in women over 70: Evaluation of rates of axillary staging and impact on adjuvant therapy in elderly women.
Di Lena É; Antoun A; Hopkins B; Barone N; Do U; Meterissian S
Surgery; 2023 Mar; 173(3):603-611. PubMed ID: 36372577
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
[TBL] [Abstract][Full Text] [Related]
16. Potential Impact of the Z0011 Trial on the Omission of Axillary Dissection: A Retrospective Cohort Study.
Shinzato JY; Serra KP; Eugeni C; Cabello C; Cardoso-Filho C; Zeferino LC
Rev Bras Ginecol Obstet; 2021 Apr; 43(4):297-303. PubMed ID: 33784760
[TBL] [Abstract][Full Text] [Related]
17. Comparison of survival outcomes between axillary conservation and axillary lymph node dissections in N1 early breast cancer: a propensity-matched SEER analysis.
Wu N; Su X; Tan Q; Luo J; Yuan Y; Hou L; Li J
Clin Transl Oncol; 2023 Apr; 25(4):1091-1101. PubMed ID: 36515887
[TBL] [Abstract][Full Text] [Related]
18. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
19. The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study.
Poodt IGM; Rots ML; Vugts G; van Dalen T; Kuijer A; Vriens BEPJ; Nieuwenhuijzen GAP; Schipper RJ
Eur J Surg Oncol; 2018 Aug; 44(8):1151-1156. PubMed ID: 29580733
[TBL] [Abstract][Full Text] [Related]
20. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy.
Leonardi MC; Arrobbio C; Gandini S; Volpe S; Colombo F; La Rocca E; Galimberti V; Kahler-Ribeiro-Fontana S; Fodor C; Dicuonzo S; Rojas DP; Zerella MA; Morra A; Montagna E; Colleoni M; Mazzarol G; Travaini LL; Zaffaroni M; Veronesi P; Orecchia R; Jereczek-Fossa BA
Radiother Oncol; 2021 Oct; 163():128-135. PubMed ID: 34461184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
